Search research articles
Contact Us
Filters
Showing results (11-20 of 169) with videos related to
Page
of 17
Sort By:
Annales De Medecine Interne
|
December 6, 2000
[Secondary osteoporosis and glucocorticoid-induced osteoporosis]
P Orcel, S M Krane
Therapeutics and Clinical Risk Management
|
May 14, 2008
Use of zoledronic acid in the treatment of Paget's disease
Margaret Seton, Stephen M Krane
Matrix (Stuttgart, Germany). Supplement
|
January 1, 1992
Site-directed mutagenesis of type I collagen: effect on susceptibility to collagenase
S M Krane, R Jaenisch
Oncogene
|
April 18, 1996
NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice
I M Krane, P Leder
Bone
|
May 20, 2008
Matrix metalloproteinases and bone
Stephen M Krane, Masaki Inada
The Journal of Clinical Endocrinology and Metabolism
|
January 1, 1984
Serum levels of type I and III procollagen fragments in Paget's disease of bone
L S Simon, S M Krane, P D Wortman, et al.
European Journal of Rheumatology and Inflammation
|
January 1, 1990
Clinical implications of cartilage metabolism in arthritis
S M Krane, M B Goldring
The Journal of Clinical Investigation
|
January 1, 1976
Abnormal properties of collagen lysyl hydroxylase from skin fibroblasts of siblings with hydroxylysine-deficient collagen
R S Quinn, S M Krane
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
July 27, 2007
Comparative functional analysis of aquaporins/glyceroporins in mammals and anurans
Carissa M Krane, David L Goldstein
Clinical Orthopaedics and Related Research
|
April 1, 1987
Metabolic consequences of bone turnover in Paget's disease of bone
S M Krane, L S Simon
Page
of 17
Search research articles
Search
Showing results (11-20 of 169) with videos related to
Sort By:
Page
of 17
Annales De Medecine Interne
|
December 6, 2000
[Secondary osteoporosis and glucocorticoid-induced osteoporosis]
P Orcel, S M Krane
Therapeutics and Clinical Risk Management
|
May 14, 2008
Use of zoledronic acid in the treatment of Paget's disease
Margaret Seton, Stephen M Krane
Matrix (Stuttgart, Germany). Supplement
|
January 1, 1992
Site-directed mutagenesis of type I collagen: effect on susceptibility to collagenase
S M Krane, R Jaenisch
Oncogene
|
April 18, 1996
NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice
I M Krane, P Leder
Bone
|
May 20, 2008
Matrix metalloproteinases and bone
Stephen M Krane, Masaki Inada
The Journal of Clinical Endocrinology and Metabolism
|
January 1, 1984
Serum levels of type I and III procollagen fragments in Paget's disease of bone
L S Simon, S M Krane, P D Wortman, et al.
European Journal of Rheumatology and Inflammation
|
January 1, 1990
Clinical implications of cartilage metabolism in arthritis
S M Krane, M B Goldring
The Journal of Clinical Investigation
|
January 1, 1976
Abnormal properties of collagen lysyl hydroxylase from skin fibroblasts of siblings with hydroxylysine-deficient collagen
R S Quinn, S M Krane
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
July 27, 2007
Comparative functional analysis of aquaporins/glyceroporins in mammals and anurans
Carissa M Krane, David L Goldstein
Clinical Orthopaedics and Related Research
|
April 1, 1987
Metabolic consequences of bone turnover in Paget's disease of bone
S M Krane, L S Simon
Page
of 17